Solentim & Valitacell announce €3.5m funding
A consortium, consisting of Valitacell, Solentim and Microcoat, has been awarded €2.5million under the highly competitive H2020 Fast Track to Innovation (FTI) initiative, and a further €1million from other sources
Aaron Figg, Director
"We strive to support our customers in developing more and better biopharmaceuticals to treat patients. By continually innovating to create unique and unrivalled technologies, we bring practical solutions to the problems of the drug discovery and development process"
Optimising workflows
We provide solutions for customers working across cell line development:
Novel Biotherapeutics
Isolate, screen and characterise attributes for clones producing novel recombinant proteins e.g. monoclonal antibodies or therapeutic proteins for rare diseases
Biosimilars and Biobetters
Generate stable cell lines to create equivalents (Biosimilars) or improved versions (Biobetters) of existing blockbuster therapeutic antibodies for which the patent has, or will shortly, expire
Gene Therapy & CAR-T
Develop new, stable, producer cell lines manufacturing viruses to subsequently infect target cells of patients
Gene Editing & Cell Engineering
Optimise your drug discovery process using targeted gene editing to create stable cell lines as cellular reagents, for use in target validation, functional genomics and disease modelling
VIEW OUR WEBINAR
"How a Top-5 Pharma Doubled the Speed of Cell Line Development"
Latest News
Postcard from BPI Europe in Vienna – Highlights of the Cell Line Development Stream
This annual meeting in early Spring is always a good forum for major new product and technology announcements. In previous years, discussions often mainly centred around assurance of clonality and
Conference News Item: Solentim presenting two posters at ESACT 2019
Solentim, a global leader in cell line development instrumentation, is pleased to announce it will be attending the 26th ESACT Meeting, 5th – 8th May 2019 in Copenhagen, Denmark. Experts
Valitacell and Solentim secure €3.5m funding to optimise the development of new biologics and cell therapies
Left to right: Ian Taylor, CCO, Solentim; Jerry Clifford, COO, Valitacell; Aaron Figg, Director, Solentim; Carolanne Doherty, Sales & Marketing Manager, Valitcell A consortium, consisting of
Solentim, along with collaborator Janssen, and partners ATUM and Valitacell, will be making a splash at BPI Europe
Solentim, a global leader in cell line development instrumentation, will be attending and exhibiting at BPI Europe, 2-5 April, in Vienna, Austria. Experts from the Company will be on hand
Important considerations for optimising outgrowth from single cells in cloning plates during cell line development
When developing biotherapeutics there are many parts of the process that require optimisation. Cell line development is a key part of this process and there are many aspects where changes
Connect with Solentim at IMAPAC: Biologics World Nordic 2019
Solentim, a global leader in cell line development instrumentation, will be attending IMAPAC’s Biologics World Nordic event, 5-7 March in Stockholm. Experts from the Company will be on hand throughout
Solentim to present and exhibit at BioProcess International Asia
Solentim is delighted to announce it will be speaking and exhibiting at BioProcess International Asia (BPI Asia), taking place 27-28th February in Tokyo, Japan. BPI Asia is a truly international event,
Valitacell and Solentim announce collaboration to accelerate discovery and development of biologic drugs and advanced cell therapies
21st February 2019: Valitacell, a biotechnology company transforming cell-based manufacturing, and Solentim, a global leader in cell line development instrumentation, today announced a new collaboration to enable earlier identification
Solentim to Present and Exhibit at the ELRIG “CRISPR in Drug Discovery 2019” Conference in Oxford, UK
NEWS – Bournemouth, 11th February 2019: Solentim, a global leader in cell line development instrumentation, is pleased to announce they will be attending the ELRIG CRISPR in Drug Discovery 2019: From
Collaboration: changing CLD practices
In January 2019 Solentim, a global leader in cell line development (CLD) instrumentation, and bioengineering company ATUM, announced a technology partnering and collaboration agreement to enable rapid, high expression, stable cell